| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8410721 | Drug Discovery Today | 2013 | 14 Pages |
Abstract
⺠Improvement of NSCLC patients outcome with conventional cytotoxic agents is poor. ⺠Many processes involved in NSCLC development and genetic aetiology have been defined. ⺠EGFR and c-MetR mutants in NSCLC are intriguing targets for specific inhibitors. ⺠Drug resistance might be overcome targeting Cancer-Initiating Cells. ⺠Combination of targeted and standard therapies is promising in NSCLC management.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Roberto E. Favoni, Angela Alama,